Cargando…

EML4-ALK fusion gene in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a malignant tumor with a high morbidity and mortality rate that is a threat to human health. With the development of molecular targeted research, breakthroughs have been made on the molecular mechanism of lung cancer. The echinoderm microtubule-associated protei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lei, Yu, Lei, Yan, Shi, Xiang, Wang, Jingjing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344266/ https://www.ncbi.nlm.nih.gov/pubmed/35928804 http://dx.doi.org/10.3892/ol.2022.13397

Ejemplares similares

EML4-ALK Fusion Gene in Korean Non-Small Cell Lung Cancer
por: Jin, Guang, et al.
Publicado: (2012)

The Author Response: EML4-ALK Fusion Gene in Korean Non-Small Cell Lung Cancer
por: Park, Jae Yong
Publicado: (2012)

Clinicopathological Characteristics of Patients with Non-Small-Cell Lung Cancer Who Harbor EML4-ALK Fusion Gene: A Meta-Analysis
por: Zhao, Fengzhi, et al.
Publicado: (2015)

Comparison of EML4-ALK fusion gene positive rate in different detection methods and samples of non-small cell lung cancer
por: Lu, Shan, et al.
Publicado: (2020)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer
por: Wen, Miaomiao, et al.
Publicado: (2016)

Clinicopathologic Features of Patients with Non-Small Cell Lung Cancer Harboring the EML4-ALK Fusion Gene: A Meta-Analysis
por: Wang, Ying, et al.
Publicado: (2014)

Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma
por: Jiang, Quan, et al.
Publicado: (2017)

Targeting EML4-ALK gene fusion variant 3 in thyroid cancer
por: Aydemirli, Mehtap Derya, et al.
Publicado: (2021)

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
por: Tanizaki, J, et al.
Publicado: (2012)

Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report
por: Wang, Mingting, et al.
Publicado: (2022)

EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers
por: Fukuyoshi, Y, et al.
Publicado: (2008)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
por: Lin, Yen-Ting, et al.
Publicado: (2019)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma
por: Heriyanto, Didik S., et al.
Publicado: (2020)

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
por: Thunnissen, Erik, et al.
Publicado: (2012)

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
por: Harada, Daijiro, et al.
Publicado: (2021)

Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer
por: Li, Ying, et al.
Publicado: (2013)

Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA
por: Gococo-Benore, Denise A, et al.
Publicado: (2022)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

Targeting stemness is an effective strategy to control EML4-ALK(+) non-small cell lung cancer cells
por: Oh, Se Jin, et al.
Publicado: (2015)

Letter to the Editor: Detection of EML4-ALK and Other ALK Fusion Genes in Lung Cancer: A Lesson from the Leukemia Fusion Gene Analysis and Future Application
por: Park, Tae Sung, et al.
Publicado: (2012)

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion
por: Aguado, Cristina, et al.
Publicado: (2018)

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
por: Paliouras, Athanasios R, et al.
Publicado: (2020)

Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
por: Lei, Xi, et al.
Publicado: (2022)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

Endobronchial Metastases in Lung Cancer Harboring EML4-ALK Rearrangement
por: Ijichi, Miharu, et al.
Publicado: (2022)

Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer
por: Xiao, DeSheng, et al.
Publicado: (2016)

Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
por: Kemper, Marcel, et al.
Publicado: (2021)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022)

EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation
por: Li, Ying, et al.
Publicado: (2021)

Frequency and clinical relevance of EGFR mutations and EML4–ALK translocations in octogenarians with non-small cell lung cancer
por: Tufman, Amanda, et al.
Publicado: (2017)

EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries
por: Elshatlawy, Mariam, et al.
Publicado: (2023)

Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report
por: Wu, Xueqian, et al.
Publicado: (2020)

Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
por: Kwon, Ji-Hyun, et al.
Publicado: (2019)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
por: Kemper, Marcel, et al.
Publicado: (2022)

Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer
por: Tan, Shuangyan, et al.
Publicado: (2018)

Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer
por: Ramshankar, Vijayalakshmi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_svvea4pr8ksg8tnk1iqsnutjhv